Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

NCT00743431 · clinicaltrials.gov ↗

COMPLETED

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: Caelyx (Pegylated Lyposomal Doxorubicin)

Sponsor

Merck Sharp & Dohme LLC